Literature DB >> 486291

Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.

L Wong, R L Nation, W L Chiou, P K Mehta.   

Abstract

1 The plasma levels of propranolol and 4-hydroxypropranolol have been measured in 17 hypertensive patients receiving chronic oral therapy with propranolol. 2 The range of plasma propranolol concentrations was from 5.3 to 300 ng/ml, and that of 4-hydroxypropranolol was from 2.1 to 36.0 ng/ml. 3 The mean (+/- s.d.) plasma concentration ratio of 4-hydroxypropranolol to propranolol was 0.130 (+/- 0.005); however, a very wide range was observed with individual values ranging from 0.057 to 0.241. 4 A statistically significant correlation was observed between the plasma concentration of 4-hydroxypropranolol and that of propranolol. 5 Propranolol and 4-hydroxypropranolol plasma concentrations were each significantly, but poorly, correlated with daily propranolol dose. 6 The clinical significance of the results has been discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 486291      PMCID: PMC1429768          DOI: 10.1111/j.1365-2125.1979.tb05815.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Clinical pharmacology of propranolol.

Authors:  A S Nies; D G Shand
Journal:  Circulation       Date:  1975-07       Impact factor: 29.690

2.  Plasma binding and the affinity of propranolol for a beta receptor in man.

Authors:  D G McDevitt; M Frisk-Holmberg; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

3.  Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography.

Authors:  T Walle; J Morrison; K Walle; E Conradi
Journal:  J Chromatogr       Date:  1975-11-26

4.  Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level.

Authors:  C R Cleaveland; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

5.  Relation of propranolol plasma level to beta-blockade during oral therapy.

Authors:  R Zacest; J Koch-Weser
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

6.  Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.

Authors:  A Hayes; R G Cooper
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

7.  High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.

Authors:  R L Nation; G W Peng; W L Chiou
Journal:  J Chromatogr       Date:  1978-05-01

Review 8.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.

Authors:  J D Fitzgerald; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1971-09       Impact factor: 8.739

10.  Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.

Authors:  Y Garceau; I Davis; J Hasegawa
Journal:  J Pharm Sci       Date:  1978-06       Impact factor: 3.534

View more
  8 in total

1.  Morphological Effects Induced In Vitro by Propranolol on Human Erythrocytes.

Authors:  Mario Suwalsky; Pablo Zambrano; Fernando Villena; Marcela Manrique-Moreno; María José Gallardo; Malgorzata Jemiola-Rzeminska; Kazimierz Strzalka; Ana María Edwards; Sigrid Mennickent; Nathan Dukes
Journal:  J Membr Biol       Date:  2015-02-28       Impact factor: 1.843

Review 2.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 3.  Pathogenesis of infantile haemangioma.

Authors:  S Greenberger; J Bischoff
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302

4.  Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

Authors:  E B Pedersen; H J Kornerup; O L Pedersen; F Andreasen; P Bjerregaard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.

Authors:  Eddy Pasquier; Joseph Ciccolini; Manon Carre; Sarah Giacometti; Raphaelle Fanciullino; Charlotte Pouchy; Marie-Pierre Montero; Cindy Serdjebi; Maria Kavallaris; Nicolas André
Journal:  Oncotarget       Date:  2011-10

6.  Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.

Authors:  Luisina M Solernó; Natasha T Sobol; María F Gottardo; Carla S Capobianco; Maximiliano R Ferrero; Liliana Vásquez; Daniel F Alonso; Juan Garona
Journal:  Sci Rep       Date:  2022-09-08       Impact factor: 4.996

7.  Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation.

Authors:  Naikhoba C O Munabi; Ryan W England; Andrew K Edwards; Alison A Kitajewski; Qian Kun Tan; Andrew Weinstein; Justin E Kung; Maya Wilcox; Jan K Kitajewski; Carrie J Shawber; June K Wu
Journal:  Stem Cells Transl Med       Date:  2015-11-16       Impact factor: 6.940

8.  Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation.

Authors:  He-Yun Cheng; Hsiu C Lin; Hsiu L Lin; Yow S Uang; Joseph J Keller; Li H Wang
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.